ArticleBMC complementary medicine and therapies2025
Antimalarial potential of Matricaria chamomilla-derived MgO nanoparticles against Plasmodium falciparum strains: an experimental study.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In silico screening for safe and potent essential oils against mosquito neural targets.Frontiers in zoology · 2026Article
- Antiplasmodial Screening of Phikud Navakot Formulation and In Vivo Evaluation, Toxicity, and Phytochemical Profiling of the PotentScientifica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe growing resistance of malaria parasites, particularly Plasmodium falciparum, to most antimalarial drugs underscores the urgent need for novel therapeutic strategies. Green-synthesized magnesium oxide nanoparticles (MgO NPs), prepared using Matricaria chamomilla, have shown promise in biomedical applications. This study presents the first evaluation of green-synthesized MgO NPs derived from M. chamomilla for their antiplasmodial effects against P. falciparum 3D7 and K1 strains.
methodsM.chamomilla extract was used for the biosynthesis of MgO NPs, which were characterized by ultraviolet-visible (UV-Vis) spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, field emission scanning electron microscopy (FESEM), dynamic light scattering (DLS), and MTT assays. The antiplasmodial activity of MgO NPs synthesized with varying solvent ratios (30:70, 50:50, and 70:30 mL of distilled water to ethanol) was evaluated in vitro.
resultsFESEM images revealed quasi-spherical MgO NPs with particle sizes ranging from 30 to 80 nm. DLS analysis showed hydrodynamic sizes of 183 nm, 161 nm, and 606 nm for the 30:70, 50:50, and 70:30 solvent ratios, respectively. The half-maximal inhibitory concentration (IC₅₀) values against the P. falciparum 3D7 strain were 0.19, 0.21, and 0.22 mg/mL for the 30:70, 50:50, and 70:30 ratios, respectively; against the K1 strain, the corresponding IC₅₀ values were 0.41, 0.45, and 0.42 mg/mL.
conclusionThe green-synthesized MgO NPs exhibited in vitro antiplasmodial activity against both chloroquine-sensitive and chloroquine-resistant P. falciparum strains. These findings support further investigation into their potential applications as antimalarial agents in preclinical models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.